🇺🇸 FDA
Patent

US 9421254

Immunostimulatory combinations of TLR ligands and methods of use

granted A61KA61K2039/55516A61K2039/55561

Quick answer

US patent 9421254 (Immunostimulatory combinations of TLR ligands and methods of use) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Aug 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Aug 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2039/55516, A61K2039/55561, A61K2039/57, A61K39/21